

Supplementary Table S1. Mean (SE) gait deficiency (%) of rats in the delayed treatment study. Animals were treated on days 23 and 30 or 57 and 64 post MMT surgery.

		Mean (SE) Gait Deficiency (%)					
Day Post Surgery	n	Sham Surgery,	MMT Surgery,	MMT Surgery	Sham Surgery,	MMT Surgery,	MMT Surgery
		Vehicle	Vehicle	Tanezumab	Vehicle	Vehicle	Tanezumab
		Control	Control	0.1 mg/kg	Control	Control	0.1 mg/kg
		Days 23, 30	Days 23, 30	Days 23, 30	Days 57, 64	Days 57, 64	Days 57, 64
-3	10	5 (2)	1 (2)	-8 (4)	2 (1)	3 (2)	1 (2)
3	10	1 (3)	21 (3)	19 (4)	2 (2)	22 (3)	19 (3)
7	10	4 (1)	14 (2)	12 (2)	3 (2)	20 (2)	14 (3)
14	10	0 (2)	7 (2)	7 (2)	-1 (2)	14 (3)	10 (2)
21	10	-3 (1)	1 (1)	4 (2)	-5 (2)	3 (2)	-2 (1)
28	10	-1 (3)	8 (2)	3 (1)	1 (20)	5 (3)	2 (2)
37	10	-4 (2)	-1 (2)	2 (2)	NA	NA	NA
42	10	NA	NA	NA	-1 (1)	6 (2)	3 (2)
56	10	NA	NA	NA	4 (2)	7 (2)	4 (2)
63	10	NA	NA	NA	0 (3)	7 (2)	4 (2)
71	10	NA	NA	NA	-2 (2)	7 (3)	3 (2)

Supplementary Table S2. Plasma (mean \pm SD) tanezumab concentrations from male Lewis rats treated weekly (SC injection). Separate mean values are provided for rats treated with 0.1 mg/kg that were ADA negative.

Termination Day	Tanezumab Dose (mg/kg/wk)	Animals	n	Tanezumab (ng/mL)		
				Day 7	Day 14	Day 28
7	0.1	All	10	468 \pm 82	-	-
7	0.1	ADA (-)	6	503 \pm 66	-	-
7	1	All	10	6843 \pm 785	-	-
7	10	All	10	60094 \pm 6157	-	-
14	0.1	All	10	543 \pm 98	781 \pm 310	-
14	0.1	ADA (-)	6	593 \pm 76	948 \pm 79	-
14	1	All	10	7894 \pm 599	12071 \pm 775	-
14	10	All	10	71853 \pm 7927	106447 \pm 7048	-
28	0.1	All	10	648 \pm 174	978 \pm 311	1364 \pm 339
28	0.1	ADA (-)	7	599 \pm 167	987 \pm 236	1463 \pm 225
28	1	All	10	7933 \pm 677	13272 \pm 790	19831 \pm 1806
28	10	All	10	64879 \pm 6497	114981 \pm 12319	163124 \pm 22790

ADA (-), animals serum-negative for anti-drug antibodies; SC, subcutaneous.